GlobeImmune, Inc., a biopharmaceutical company, focuses on developing therapeutic products for cancer and infectious diseases based on proprietary Tarmogen platforms. The company's product candidate includes GS-4774, which is in Phase 2 trials for the treatment of patients with chronically infected with hepatitis B virus, as well as with oral antiviral suppressive therapy. The company is also invo...
GlobeImmune reported revenue of $6.46 million for fiscal year 2015, up 8.2% from fiscal year 2014, and net income of -$2.77 million. In Q1 2016 (the quarter ended March 31, 2016) revenue was $942,750, down 20.6% from a year before.
Figures from company filings; latest fiscal year ended December 31, 2015.
From state WARN notices, SEC filings and news reports. Reported: news reports only. Confirmed: an official filing exists.
GlobeImmune had 0 layoffs in the last 12 months, and 1 in all (the earliest dated June 11, 2015).
Layoffs, 12 months
0
Workers not stated
Layoffs in all
1
Earliest dated Jun 11, 2015
Workers in all
-
Where the sources state it
Newest layoff
Jun 11, 2015
Announced date
| Date | Place | Workers | Status | Sources |
|---|---|---|---|---|
| Jun 11, 2015 | United States | not stated | Confirmed | SEC 8-K |
No profile data available.